Treatment patterns and symptom control in patients with GERD: US community based survey

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 1869-1878

  Chey, William D ^a   Mody, Reema R ^b   Wu, Eric Q ^c   Chen, Lei ^c   Kothari, Smita ^d   Persson, Bjorn ^c   Beaulieu, Nicolas ^c   Lu, Mei ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

^c ANALYSIS GROUP   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Gastroesophageal reflux disease; Proton pump inhibitor; Symptom control

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; BISMUTH SALICYLATE; CIMETIDINE; DIHYDROXYALUMINUM SODIUM CARBONATE; FAMOTIDINE; GAVISCON; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MYLANTA; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE; TUMS;

ADD ON THERAPY; ADULT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CONTROL; DOSAGE SCHEDULE COMPARISON; DRUG UTILIZATION; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRESCRIPTION; REVIEW; STRUCTURED QUESTIONNAIRE; TREATMENT RESPONSE;

AGED; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH CARE SURVEYS; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS; QUESTIONNAIRES; UNITED STATES;

EID: 67650834909     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903035745     Document Type: Review

References (33)

1. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-17
2. Modlin IM, Moss SF, Kidd M, et al. Gastroesophageal reflux disease: then and now. J Clin Gastroenterol 2004;38:390-402
3. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2007;5:17-26
4. An overview of gastroesophageal reflux disease. Based on a presentation by M. Michael Wolfe, MD. Am J Manag Care 2000; 6:S461-6
5. Jaspersen D, Labenz J, Willich SN, et al. Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study. Dig Liver Dis 2006;38:233-8
6. Malfertheiner P, Hallerback B. Clinical manifestations and complications of gastroesophageal reflux disease (GERD). Int J Clin Pract 2005;59:346-55
7. Association TAG. The burden of gastrointestinal disease. Bethesda, MD 2001.
8. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11
9. Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther 2006;24:259-72
10. Kaplan-Machlis B, Spiegler GE, Revicki DA. Health-related quality of life in primary care patients with gastroesophageal reflux disease. Ann Pharmacother 1999;33:1032-6
11. Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98:S8-14
12. Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252-8
13. Wahlqvist P. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life. Am J Gastroenterol 2001;96:S57-61
14. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004;22:108-14
15. Dubois RW, Aguilar D, Fass R, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. Aliment Pharmacol Ther 2007;25:487-500
16. Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an underappreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003;98:1487-93
17. Nocon M, Labenz J, Jaspersen D, et al. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care - results from the ProGERD study. Aliment Pharmacol Ther 2007;25:715-22
18. Storr M, Meining A. Pharmacologic management and treatment of gastroesophageal reflux disease. Dis Esophagus 2004; 17:197-204
19. Fass R, Bautista J, Janarthanan S. Treatment of gastroesophageal reflux disease. Clin Cornerstone 2003;5:18-29; discussion 30-11
20. Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci 2005;27:432-5
21. DeVault KR, Castell DO. Updated guideline for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200
22. The International Classification of Diseases, 9th revision, Clinical Modification, 4th edn. Washington, DC: U.S. Department of Health and Human Services, 1991.
23. Rothman M, Farup C, Stewart W, et al. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci 2001; 46:1540-9
24. Wahlqvist P, Carlsson J, Stalhammar N, et al. Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAIGERD) - results from a crosssectional study. Value Health 2002;5:106-13
25. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manage 2000; 7:29-34
26. Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006;24:377-85
27. Fass R. Proton-pump inhibitor therapy in patients with gastrooesophageal reflux disease: putative mechanisms of failure. Drugs 2007;67:1521-30
28. Fass R, Shapiro M, Dekel R, et al. Systematic review: protonpump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005;22:79-94
29. Talley NJ, Armstrong D, Junghard O, et al. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006;24:371-6
30. Coron E, Hatlebakk JG, Galmiche JP. Medical therapy of gastroesophageal reflux disease. Curr Opin Gastroenterol 2007;23: 434-9
31. Hatlebakk JG, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000;14:1267-72
32. Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther 2008;27: 473-82
33. Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26:443-52